GleamWall
中文EN

PTGX Protagonist Therapeutics, Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1377121 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY163.7%
TTM net income YoY645.5%
TTM EPS YoY616.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin58.6%
Net margin62.0%
FCF margin19.8%
EBITDA margin58.9%

Returns

ROE39.6%
ROA37.0%
ROIC (approx.)56.5%
Asset turnover0.60x

Leverage & solvency

Liabilities / assets5.4%
Debt / equity0.00x
Current ratio19.85x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.32x
Accruals ratio25.1%
Payout ratio—
Capex / revenue0.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$46.02M$434.43M
R&D expense$159.29M$138.13M
SG&A expense$44.85M$43.46M
Operating income-$158.13M$252.84M
Pretax income-$129.31M$279.41M
Income tax$838,000$4.22M
Net income-$130.15M$275.19M
EBITDA-$156.85M$253.67M
EPS (basic)-2.054.47
EPS (diluted)-2.054.23
Weighted avg. shares (diluted)63.57M65.08M
Balance sheet
Cash & equivalents$128.39M$97.47M
Short-term investments$438.97M$321.66M
Current assets$577.57M$591.64M
PP&E, net$3.86M$3.19M
Total assets$668.19M$744.73M
Current liabilities$45.44M$47.40M
Total liabilities$53.48M$69.43M
Shareholders' equity$614.71M$675.29M
Shares outstanding62.58M61.04M
Cash flow statement
Operating cash flow$57.67M$184.15M
Capital expenditure$1.59M$1.35M
Free cash flow$56.08M$182.80M
Investing cash flow-$49.33M-$299.48M
Financing cash flow$22.86M$25.85M
Depreciation & amortization$1.28M$826,000
Stock-based compensation$45.97M$37.55M

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.